Although there are now fewer allo-SCTs performed for CML, leukemic relapse post transplant remains a persistent problem. To better define clinical and biological parameters determining postrelapse outcome, we studied 59 patients with CML relapsing after HLA-identical sibling allo-SCT between 1993 and 2008. Eighteen (30.5%) were transplanted in advanced phase and 41 (69.5%) in chronic phase. With a median follow-up from relapse of 7.9 years, 5-year post relapse survival (PRS) was 62%. Multivariate analysis found disease status at transplant, time to diagnosis of relapse from transplant and pretransplant tyrosine kinase inhibitor (TKI) use as significant factors associated with PRS. Analysis of BCR-ABL transcript expression in the hematopoietic progenitor compartment was performed in 36 patients (22 relapsed, 8 non-relapsed and 6 TKI alone controls). Patients with BCR-ABL expression in their early hematopoietic stem cell compartment (Lineage − CD34 + CD38 − CD90 + ) had worse survival irrespective of the disease status. We conclude that disease status remains the strongest clinical prognostic factor for PRS in CML following allo-SCT. The persistence of BCR-ABL expression in the progenitor cell compartment in some patients after SCT emphasizes the need to target CML-leukemia stem cells.
INTRODUCTION
Allo-SCT has been used as a highly effective curative treatment for CML for 430 years, in large part because of the susceptibility of this disease, particularly in its chronic phase (CP), to the GVL effect of the incoming donor immune system. [1] [2] [3] [4] [5] As a consequence, many thousands of patients with CML have received allo-SCT worldwide and are now long-term survivors. The introduction of imatinib and other tyrosine kinase inhibitors (TKIs) relegated the place of allo-SCT in CML to second-or third-line therapy in many patients, causing significant reduction in transplants for CML. [6] [7] [8] [9] [10] [11] [12] Most CML patients who are candidates for allo-SCT in this century are patients refractory or intolerant to TKI or those with CML more advanced than first CP. [13] [14] [15] Relapse of CML after allo-SCT remains a current issue, because relapse can be delayed, occurring even in the second decade after allo-SCT, and patients transplanted in the era of TKI treatment have a higher chance of relapse, because they were transplanted for advanced or refractory disease. [16] [17] [18] Management of relapsed CML may include DLI, TKI, chemotherapy or second allo-SCT. [6] [7] [8] [9] [10] [11] 19 With the availability of TKI and improved transplant management, the factors determining outcome after post-allo-SCT relapse today are likely to differ from earlier observations. Furthermore, many questions remain unanswered about the biological basis of relapse in CML-particularly the nature of the minimal residual disease in the progenitor cell compartment responsible for relapse 20 and its relationship with treatment and post-relapse outcome. Recent studies showed that with advance to blastic phase the predominant leukemia-initiating population in CML shifts from a lineage − CD34 + CD38 − progenitor to a more differentiated granulocyte-macrophage progenitor. 21 To better define factors affecting outcome after relapse in CML and to characterize the CML progenitor populations at relapse, we studied 59 patients relapsing post allo-SCT at our institute between 1993 and 2008. In 22 relapsed patients, we correlated the pattern of BCR-ABL expression in defined subpopulations of hematopoietic stem and progenitor cells with treatment response and outcome. Here we present clinical and biological parameters that were associated with post-relapse outcome of CML following allo-SCT.
MATERIALS AND METHODS

Study population
Between September 1993 and August 2008, 109 consecutive patients with Philadelphia chromosome-positive CML underwent allo-SCT from a 6/6 HLA identical sibling in successive National Heart, Lung and Blood Institute (NHLBI) institutional review board-approved protocols (93-H-0212, 97-H-0202, 97-H-0099, 00-H-0001, 01-H-0010, 02-H-0111, 03-H-0192, 04-H-0112, 06-H-0248, 07-H-0136, 09-H-0062). Written informed consent, consistent with the Helsinki Declaration, was obtained from all patients and donors.
Transplant conditioning regimen and ex-vivo T-cell depletion Ninety six patients (88%) received a myeloablative conditioning regimen with cyclophosphamide 120 mg/kg ± fludarabine 125 mg/m 2 and TBI (1200-1360 cGy). Thirteen patients (12%) received a non-myeloablative conditioning regimen consisting of cyclophosphamide 120 mg/kg and fludarabine 125 mg/m 2 . Twenty-seven patients (25%) received BM and 82 patients (75%) received G-CSF-mobilized peripheral blood as the stem cell source. Thirteen patients (12%) given nonmyeloablative conditioning received a T-lymphocyte replete graft and 96 (88%) received a 4-log 10 exvivo T-lymphocyte depleted graft. T-cell depletion was achieved using the CellPro system (CellPro Inc., Bothel, WA, USA) before 1999, Isolex 300i (Nexell Therapeutics Inc., Irvine, CA, USA) from 1999 to 2006 and thereafter positive selection of CD34 + cells using the Miltenyi CliniMacs system (Miltenyi Biotec Inc., Auburn, CA, USA). CSA was used throughout for GVHD prophylaxis, with varied dose according to protocol. 22 In addition to CSA, MTX and/or mycophenolate mofetil were used in T-replete graft protocols.
Clinical BCR-ABL monitoring
Patients were monitored for molecular evidence of leukemia by PCR-based amplification of b2a2 and b3a2 transcripts encoding the p210 BCR-ABL fusion product. Blood samples were collected at least every 3 months up to 1 year post transplant, then at least annually thereafter. In all cases, RNA was extracted from peripheral blood leukocytes after ammonium chloride lysis of red cells, and cDNA was produced by reverse transcription using random hexamer primers. Before 2003, samples were assayed qualitatively using the double-nested PCR to amplify BCR-ABL. 23 After June 2003, a commercial real-time PCR kit (Roche, Indianapolis, IN, USA) replaced the double-nested PCR as the method to detect BCR-ABL, with G6PDH as the control gene as described previously. 24 After June 2009, the ipsogen BCR-ABL1 Mbcr Kit (Qiagen, Valencia, CA, USA) was used to measure BCR-ABL and the control gene ABL1. The double-nested assay and real-time BCR-ABL assays were all qualitatively comparable in sensitivity, detecting BCR-ABL transcripts in K562 RNA diluted to 1:100 000-1 000 000 in control RNA. To facilitate serial monitoring over time and to reconcile the different techniques used for BCR-ABL measurement, positive values obtained with the older assay were mathematically 'converted' to units of BCR-ABL: ABL1 based on a good linear log-log relationship (r 2 0.883, Po0.001) between values obtained in parallel measurements of 50 positive clinical samples with both assays. In this study, we defined a sample positive for BCR-ABL if a detectable band was noted in a double-nested assay or if either of the two duplicate samples generated a measurable crossing point in the realtime PCR assay. Samples were considered negative, if no BCR-ABL band or crossing point was detected, and the housekeeper gene expression assay confirmed good control gene expression. 25 Definition and management of relapse CP is defined as first chronic phase, while blast crisis, accelerated phase and second chronic phase were categorized as advanced-phase (AP) disease. Molecular relapse was defined as a detectable BCR-ABL transcript level by PCR on 42 consecutive occasions, requiring salvage treatments. Hematological relapse followed the Center for International Blood and Marrow Transplant Research criteria. 26 For relapsed patients, the BCR-ABL patterns were further classified into two categories. Patients who had consecutively positive BCR-ABL postrelapse were categorized as persistently positive. Patients who remained BCR-ABL negative for ⩾ 2 consecutive readings after initial positive readings post transplant were categorized as persistently negative. Molecular relapse was treated with DLI with or without imatinib 400-600 mg/day. Hematological relapse was treated at the investigator's discretion with imatinib, other TKI, interferon α or second SCT as previously described. 19, 27 Concurrent TKI and DLI was defined as the initiation of both treatments within 6 months of each other.
Measurement of BCR-ABL in the hematopoietic progenitor cell compartment
Cell samples. Mononuclear cells from peripheral blood or BM were isolated by density gradient centrifugation (OrganonTeknika, Durham, NC, USA) and cryopreserved in RPMI1640 supplemented with 20% fetal calf serum and 10% dimethyl sulfoxide. After thawing, CD34 + cells were selected by immunomagnetic beads (MiniMACS, Miltenyi Biotech). Sample Abbreviations: AP = advanced phase; aGVHD = acute GVHD; cGVHD = chronic GVHD; CP = chronic phase; IST = immunosuppressive therapy; TKI = tyrosine kinase inhibitor.
date varied among the subjects, but all samples from relapsed patients were collected when the concurrent peripheral blood showed either positive BCR-ABL or hematological relapse after the diagnosis of relapse (median time from diagnosis of relapse to sample collection was 386 days).
Six patients who were on TKI alone and never received allo-SCT served as controls (Supplementary Table S1 ). Figure S1) . 29 Real-time quantitative PCR (RQ-PCR). Total RNA was extracted from sorted CD34 + subpopulations using the RNeasy kit (Qiagen), and cDNA synthesized using the Advantage RT-for-PCR kit (Clontech, Mountain View, CA, USA). ABL1 expression was used as the endogenous cDNA control. 30 BCR-ABL transcripts were assessed according to a minimal residual disease detection assay using the recommended standardized probe and primers. 31 All reactions by RQ-PCR using the ABI PRISM 7900 system (Applied Biosystems, Foster City, CA, USA) were performed in triplicate. BCR-ABL RQ-PCR reactions consistently detected one leukemic cell in 1 000 000 non-leukemic cells.
Statistical methods
Patient characteristics were described by the frequencies and sample proportions and compared by the Fisher's exact test between subgroups. Kaplan-Meier estimates were used to estimate time-to-event distributions of OS post-transplant and postrelapse survival (PRS), with PRS defined as the time from first relapse until last follow-up. Log-rank tests were used to compare the survival curves. For the analysis of progenitor cell compartment BCR-ABL measurement, as the timing of sample collection is not always identical to the diagnosis of relapse, we analyzed the data according to the disease status at transplant rather than the type of relapse. Also, time from sample collection to last follow-up was used as a surrogate end point for PRS in this subgroup analysis. Cox proportional hazards regression models were used to examine the prognostic factors associated with PRS. Backward stepwise selection was used to determine the parsimonious multivariate models. The proportional hazards assumption is tested using the scaled Schoenfeld residuals, and there was no evidence for non-proportionality in any of the models presented. All tests were two-sided, and a P-value o0.05 was used for statistical significance. Abbreviations: AP = advanced phase; aGVHD = acute GVHD; cGVHD = chronic GVHD; CP = chronic phase; IST = immunosuppressive therapy; TKI = tyrosine kinase inhibitor.
Analysis was performed using the SAS statistical software (version 9.3, SAS Institute Inc., Cary, NC, USA). Graphs were created using Prism 5.03 (GraphPad Software, Inc. La Jolla, CA, USA).
RESULTS
Characteristics of relapsed patients
One hundred and nine patients received allo-SCT between 1993 and 2008. Eighty-three patients (76%) were in CP at transplant and 93 patients (84.5%) had never received TKI prior to transplantation. Fifty-nine patients (54%) relapsed (37 molecular and 22 hematological) and the median time from transplant to relapse was 1 year (363 days, range: 16-3773 days). Twenty (34%) patients died, 16 (80%) following relapse and 4 (20%) from non-relapse causes. Tenyear OS post transplant was 65% in relapsed patients. The characteristics of relapsed patients are described in (Figures 1a and b) . Earlier relapse post transplant was associated with poor PRS (P o0.001), with 5-year PRS rate of 33, 67 and 93% for patients with diagnosis of relapse within 100 days, between 100 days to 1 year and after 1 year from transplant, respectively ( Figure 1c ). In contrast, age at transplant, age at relapse, gender, female-to-male transplant, graft source, recipient CMV serostatus, donor CMV serostatus, acute GvHD, pretransplant TKI use, DLI or concurrent DLI with TKI had no impact on PRS. Pretransplant TKI use showed a favorable trend on PRS after stratifying by the disease status (Figure 1d ). In addition, patients with a persistently positive BCR-ABL pattern had a 5-year PRS of 41% compared with 100% for persistently negative pattern (P o 0.001). In a univariate Cox model with a time-dependent covariate, the post-relapse TKI use had no effect on PRS. Multivariate analyses were performed to adjust for potential confounding factors. In the Cox regression models with backward elimination, significant factors associated with PRS were disease status, pretransplant TKI use and time to diagnosis of relapse from transplant. These factors remained significant after controlling for age at relapse, gender, female-to-male transplant and graft source. Because 19/20 deaths were observed in the subgroups of patients with hematological relapse (N = 22) or persistent positive BCR-ABL (N = 33), the Cox models were also performed separately for these subgroups, and similar results were obtained (Table 3) . Interestingly, pretransplant TKI was found to be a protective factor for longer PRS after adjusting for the disease status and time to diagnosis of relapse from transplant, especially for high-risk patients with hematological relapse or persistent positive BCR-ABL.
BCR-ABL expression in progenitor cells
To evaluate biological characteristics of CML relapse after allo-SCT, we performed BCR-ABL analysis of the hematopoietic progenitor compartment in 36 patients (22 relapsed, 8 non-relapsed patients and 6 TKI only controls). The characteristics of these 22 relapsed patients were not significantly different from the entire relapsed cohort (Supplementary Table S2 ). The distribution pattern of absolute numbers of progenitors sorted in the three compartments did not differ between relapsed and non-relapsed samples (Figure 2a) . Seventy-seven percent of relapsed samples harbored the BCR-ABL transcript in at least one of the progenitor cell compartments (HSCs, CMP or GMP), indicating relapse could first be detected as an expansion in any of the three progenitor compartments (Figure 2b ). BCR-ABL transcripts were generally more detectable in the CMP/GMP compartment compared with the HSC group, irrespective of the time to diagnosis of relapse (Supplementary Figure S2) In AP, significantly higher BCR-ABL transcripts were detected in the CMP compartment (P o 0.017) compared with that in CP. BCR-ABL transcripts in HSC and GMP compartments were not significantly different between AP and CP. The distribution of BCR-ABL transcript in progenitor cell compartment in each individual sample was heterogeneous according to the disease status. In eight CP, the BCR-ABL transcript levels were detected predominantly in the HSC compartment (Figure 3a) , while in three CP, they were detected predominantly in the CMP/GMP compartment ( Figure 3b) ; and five had no detectable BCR-ABL transcripts. In contrast in three AP, BCR-ABL transcript levels were detected predominantly in the CMP/GMP compartment (Figure 3c) , while in the other three AP, the BCR-ABL transcript levels were detected predominantly in the HSC compartment (Figure 3d ). Therefore we categorized the BCR-ABL distribution pattern into (1) non-detectable BCR-ABL in the progenitor cells, (2) HSC predominant or (3) CMP/GMP predominant. The BCR-ABL distribution pattern in progenitor cell compartment was highly correlated with PRS (P = 0.008; Figure 4 ).
DISCUSSION
In this study, we explored the features that affected the outcome of 59 patients relapsing after SCT for CML. This is the first detailed clinical and biological analysis of post-relapse outcome in CML in the modern therapeutic era. Unlike AML, which rarely recurs after 3 years post transplant, late relapses at prolonged intervals from SCT occur in CML. [16] [17] [18] However, little is known about the mechanisms underlying relapse of CML after transplant. It is suggested that long-lived leukemia-initiating progenitors of CML persist in a dormant state. 32, 33 In this model, the GVL effect is constantly needed to hold leukemia-initiating cells from causing a relapse. 34 Abbreviations: AP = advanced phase; CI = confidence interval; HR = hazard ratio; TKI = tyrosine kinase inhibitor. 
Number of cells
Relapsed samples The characteristics of CML relapse after allo-SCT may vary depending on the status of the disease at transplant and exposure to TKI pretransplant. Of the 20 patients who died after relapse in this series, all but one died directly of leukemia. We therefore have used survival postrelapse as a surrogate for treatment success. Treatment for relapse included DLI, TKI, combinations of both with or without interferon or second transplant. We previously reported the synergy between TKI and DLI in a smaller subset of this series with a shorter follow-up. 19 Although there was an early survival advantage for use of DLI in addition to TKI, this significance is lost after longer follow-up. As is well established, we found that disease status at transplant was the major factor determining survival after relapse. 35 We also found earlier relapse from transplant, and the absence of pretransplant TKI exposure were significantly associated with poor survival after relapse. In addition, postrelapse BCR-ABL pattern was highly correlated with PRS, with patients who had persistently negative BCR-ABL surviving longer than those persistently positive as reported previously. 32 The post-hoc power analysis showed that our study has 80% power to detect a hazard ratio of 4 (or 0.25) with a twosided significance level of 0.05, thus our study would have limited power to identify risk factors with smaller effect. Nevertheless, all factors associated with poor post-relapse outcomes may be explained by the persistence of minimal residual disease. Therefore, we speculate that the leukemic HSC population might be the source of minimal residual disease and the last cell population to be eradicated by GVL. Analysis of BCR-ABL in the progenitor cell compartments permitted a further categorization of post-relapse outcome. In CP, we found that the presence of BCR-ABL expression in the HSC compartment was associated with poorer outcome compared with the group with BCR-ABL expression either predominant in the GMP/CMP compartment or undetectable in any progenitor cell compartment. In AP, all patients had BCR-ABL transcript in the CMP/GMP compartment as described previously; 21 however, those with the worst prognosis had a predominance of BCR-ABL in the HSC compartment. The underlying biology of the leukemia stem cell in AP may affect immunogenicity, rendering them more resistant to GVL in comparison to CP, thus accounting for the poorer outcome in patients who are transplanted in AP, and poorer response clinically to DLI. Alternatively, leukemia HSC susceptibility to immune attack may be similar between CP and AP. Relapse therefore arises due to the persistence of a critical number of such cells, which in our study rendered them detectable. This critical number of leukemic stem cells would, stochastically, result in a greater probability of the emergence of a cell that has developed immunological 36 or pharmacological resistance 37 or both and, intrinsically, also has the ability to propagate leukemia. In our study, the sample size available for the analysis of progenitor cell compartment is too small to make a conclusion; however, we hope our data may encourage further research to answer these hypothesis.
In summary, while relapse of CML post-allo-SCT is often considered a relatively easily treated complication with a favorable outcome, this is only true for molecular relapse in patients with CP. Our study draws attention to a significant overall mortality following relapse of CML post transplant (5-year mortality 30%). Therefore newer agents are required to manage post-transplant relapse in CML patients especially targeting the HSC compartment, particularly in AP. 
